Literature DB >> 21835155

Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

Allan Lawrie1, Abdul G Hameed, Janet Chamberlain, Nadine Arnold, Aneurin Kennerley, Kay Hopkinson, Josephine Pickworth, David G Kiely, David C Crossman, Sheila E Francis.   

Abstract

Inflammatory mechanisms are proposed to play a significant role in the pathogenesis of pulmonary arterial hypertension (PAH). Previous studies have described PAH in fat-fed apolipoprotein E knockout (ApoE(-/-)) mice. We have reported that signaling in interleukin-1-receptor-knockout (IL-1R1(-/-)) mice leads to a reduction in diet-induced systemic atherosclerosis. We subsequently hypothesized that double-null (ApoE(-/-)/IL-1R1(-/-)) mice would show a reduced PAH phenotype compared with that of ApoE(-/-) mice. Male IL-1R1(-/-), ApoE(-/-), and ApoE(-/-)/IL-1R1(-/-) mice were fed regular chow or a high-fat diet (Paigen diet) for 8 weeks before phenotyping for PAH. No abnormal phenotype was observed in the IL-1R1(-/-) mice. Fat-fed ApoE(-/-) mice developed significantly increased right ventricular systolic pressure and substantial pulmonary vascular remodeling. Surprisingly, ApoE(-/-)/IL-1R1(-/-) mice showed an even more severe PAH phenotype. Further molecular investigation revealed the expression of a putative, alternatively primed IL-1R1 transcript expressed within the lungs but not aorta of ApoE(-/-)/IL-1R1(-/-) mice. Treatment of ApoE(-/-) and ApoE(-/-)/IL-1R1(-/-) mice with IL-1-receptor antagonist prevented progression of the PAH phenotype in both strains. Blocking IL-1 signaling may have beneficial effects in treating PAH, and alternative IL-1-receptor signaling in the lung may be important in driving PAH pathogenesis.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835155      PMCID: PMC3181351          DOI: 10.1016/j.ajpath.2011.06.037

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Comparison between prospective and retrospective triggering for mouse cardiac MRI.

Authors:  Edwin Heijman; Wolter de Graaf; Petra Niessen; Arno Nauerth; Guillaume van Eys; Larry de Graaf; Klaas Nicolay; Gustav J Strijkers
Journal:  NMR Biomed       Date:  2007-06       Impact factor: 4.044

2.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.

Authors:  R C Trembath; J R Thomson; R D Machado; N V Morgan; C Atkinson; I Winship; G Simonneau; N Galie; J E Loyd; M Humbert; W C Nichols; N W Morrell; J Berg; A Manes; J McGaughran; M Pauciulo; L Wheeler
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

3.  PPARdelta inhibits IL-1beta-stimulated proliferation and migration of vascular smooth muscle cells via up-regulation of IL-1Ra.

Authors:  H J Kim; M Y Kim; J S Hwang; H J Kim; J H Lee; K C Chang; J-H Kim; C W Han; J-H Kim; H G Seo
Journal:  Cell Mol Life Sci       Date:  2010-03-10       Impact factor: 9.261

4.  Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.

Authors:  Kwon-Ho Hong; Young Jae Lee; Eunji Lee; Sung Ok Park; Chul Han; Hideyuki Beppu; En Li; Mohan K Raizada; Kenneth D Bloch; S Paul Oh
Journal:  Circulation       Date:  2008-07-28       Impact factor: 29.690

5.  Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis.

Authors:  Alexi Crosby; Frances M Jones; Mark Southwood; Susan Stewart; Ralph Schermuly; Ghazwan Butrous; David W Dunne; Nicholas W Morrell
Journal:  Am J Respir Crit Care Med       Date:  2009-12-03       Impact factor: 21.405

6.  Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension.

Authors:  Margaret R MacLean; Graeme A Deuchar; Martin N Hicks; Ian Morecroft; Sanbing Shen; John Sheward; Janet Colston; Lynn Loughlin; Margaret Nilsen; Yvonne Dempsie; Anthony Harmar
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

7.  ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.

Authors:  Andriy O Samokhin; Frank Bühling; Franz Theissig; Dieter Brömme
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

8.  Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.

Authors:  N F Voelkel; R M Tuder; J Bridges; W P Arend
Journal:  Am J Respir Cell Mol Biol       Date:  1994-12       Impact factor: 6.914

9.  Left ventricular hypertrophy in mice with a cardiac-specific overexpression of interleukin-1.

Authors:  Kenichiro Nishikawa; Mikoto Yoshida; Masatoshi Kusuhara; Norio Ishigami; Kikuo Isoda; Kohji Miyazaki; Fumitaka Ohsuzu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-02-10       Impact factor: 4.733

10.  Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding.

Authors:  Janet Chamberlain; Sheila Francis; Zoe Brookes; Gary Shaw; Delyth Graham; Nicholas J Alp; Steven Dower; David C Crossman
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

View more
  40 in total

1.  Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Authors:  Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

2.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

4.  Modulation of Intersectin-1s Lung Expression Induces Obliterative Remodeling and Severe Plexiform Arteriopathy in the Murine Pulmonary Vascular Bed.

Authors:  Monal Patel; Dan Predescu; Cristina Bardita; Jiwang Chen; Niranjan Jeganathan; Melanie Pritchard; Salvatore DiBartolo; Roberto Machado; Sanda Predescu
Journal:  Am J Pathol       Date:  2017-01-06       Impact factor: 4.307

5.  Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.

Authors:  Eleonora Mezzaroma; Ross B Mikkelsen; Stefano Toldo; Adolfo G Mauro; Khushboo Sharma; Carlo Marchetti; Asim Alam; Benjamin W Van Tassell; David A Gewirtz; Antonio Abbate
Journal:  Mol Med       Date:  2015-03-26       Impact factor: 6.354

Review 6.  The Future of Vascular Biology and Medicine.

Authors:  Scott Kinlay; Thomas Michel; Jane A Leopold
Journal:  Circulation       Date:  2016-06-21       Impact factor: 29.690

Review 7.  A New Frontier in Immunometabolism. Cholesterol in Lung Health and Disease.

Authors:  Michael B Fessler
Journal:  Ann Am Thorac Soc       Date:  2017-11

Review 8.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

Review 9.  Pulmonary vascular dysfunction in metabolic syndrome.

Authors:  Conor Willson; Makiko Watanabe; Atsumi Tsuji-Hosokawa; Ayako Makino
Journal:  J Physiol       Date:  2018-09-12       Impact factor: 5.182

10.  Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension.

Authors:  Seungbum Kim; Katya Rigatto; Marcelo B Gazzana; Marli M Knorst; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Hypertension       Date:  2020-02-24       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.